ArticleNature medicine2020
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China.
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 258 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver （CQMU）
Safety and Immune Response of COVID-19 Vaccination in Overweight People With Excessive BMI
Who cites it
258 citing papers in PubMed, 8 syntheses or guidelines pooled it, 452 citations in OpenAlex.
- Seroprevalence of SARS-CoV-2 Antibodies in Africa: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis.Reviews in medical virology · 2022Pooled it
- The seroprevalence of SARS-CoV-2 antibodies among health care workers before the era of vaccination: a systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Pooled it
- High seroprevalence for SARS-CoV-2 infection in South America, but still not enough for herd immunity!International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 1).Annals of internal medicine · 2021Guideline
- Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2021Pooled it
- SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Pooled it
- Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis.The Journal of hospital infection · 2021Pooled it
- COVID-19 serology in nephrology healthcare workers.Wiener klinische Wochenschrift · 2021Trial
- Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown.Scientific reports · 2021Trial
- Systematic evaluation of IgG responses to SARS-CoV-2 spike protein-derived peptides for monitoring COVID-19 patients.Cellular & molecular immunology · 2021Trial
- Trial
- Gut microbial allies and adversaries in SARS-CoV-2 infection.Current research in microbial sciences · 2026Article
- SARS-CoV-2 seroprevalence in Barcelona and Catalonia (Spain) after the 2020 lockdown.Scientific reports · 2026Article
- Estimating the incidence of SARS-CoV-2 infections by jointly modelling seroprevalence, hospitalization and mortality data, February 2020 - January 2021, Belgium.Archives of public health = Archives belges de sante publique · 2026Article
- Flow cytometric analysis of the SARS coronavirus 2 antibodies in human plasma.Scientific reports · 2025Article
- Mapping the viral battlefield: SARS-CoV-2 infection dynamics among healthcare workers in Brazil.Human resources for health · 2025Article
- National and sub-national sero-epidemiology of immunoglobulin G against SARS-CoV-2 in Iran in 2021.PloS one · 2025Article
- SARS-CoV-2 seroprevalence among learners in grades 1-7, their parents and teachers in KwaZulu-Natal, South Africa: a cross-sectional study.Frontiers in public health · 2025Article
- Enhanced immunity against SARS-CoV-2 in returning Chinese individuals.Human vaccines & immunotherapeutics · 2024Article
198 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
22 authors at 13 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased. Patients who visited a hospital for maintenance hemodialysis and healthcare workers also had a higher seroprevalence of 3.3% (51 of 1,542, 2.5-4.3%, 95% confidence interval (CI)) and 1.8% (81 of 4,384, 1.5-2.3%, 95% CI), respectively. More studies are needed to determine whether these results are generalizable to other populations and geographic locations, as well as to determine at what rate seroprevalence is increasing with the progress of the COVID-19 pandemic. Serologic surveillance has the potential to provide a more faithful cumulative viral attack rate for the first season of this novel SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.